Clobazam

Evidence Level: L5

Predicted Indications: 10

Clobazam

Pharmacist Assessment Report

One-Sentence Summary

Clobazam is a benzodiazepine antiseizure medication that acts on GABA-A receptors and is marketed in Canada. The TxGNN model predicts it may be useful for febrile infection-related epilepsy syndrome, a severe form of refractory status epilepticus that begins in previously healthy children. There are no registered clinical trials and 2 publications in this area; neither studies clobazam directly (they cover enteral lorazepam and perampanel), so the evidence is indirect.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	febrile infection-related epilepsy syndrome
TxGNN Prediction Score	0.9982
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Clobazam is a 1,5-benzodiazepine that enhances GABA-A receptor signalling. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description relies on the drug’s known class behaviour. Enhancing inhibitory GABA signalling is a reasonable approach for prolonged, repetitive seizures such as those seen in refractory status epilepticus.

Febrile infection-related epilepsy syndrome (FIRES) is a type of new-onset refractory status epilepticus in previously healthy children. Benzodiazepines are used as part of the acute seizure management, which gives a class-level reason why clobazam might fit. However, FIRES is thought to be driven largely by neuroinflammation and usually resists standard antiseizure drugs, so a GABAergic mechanism alone is unlikely to be enough.

The two retrieved papers examine other agents: enteral lorazepam as a weaning strategy from midazolam, and perampanel for reducing barbiturate dependence. Neither tests clobazam. The support is therefore class-level and indirect, and the score reflects a model prediction rather than demonstrated benefit. Because no cited study addresses clobazam in this disease, the evidence level is L5.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35770765	2022	Case series	Epileptic Disorders	Enteral lorazepam was an effective substitute for weaning midazolam-dependent patients with FIRES (not clobazam)
39958143	2025	Case report	Cureus	Perampanel may reduce barbiturate dependency in a 13-year-old boy with FIRES (not clobazam)

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02238334	TEVA-CLOBAZAM	Not recorded	Not recorded
02244638	APO-CLOBAZAM	Not recorded	Not recorded

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction database. Examples of major-level interactions include morphine (including liposomal morphine) and eliglustat. Moderate-level examples include bupropion, aprepitant, omeprazole, esomeprazole, lansoprazole, cimetidine, clarithromycin, metoclopramide, fenfluramine and dronabinol. Antacids such as magnesium oxide, aluminum hydroxide and calcium carbonate are minor-level.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but no clinical trial or publication tests clobazam in febrile infection-related epilepsy syndrome. The only support is class-level benzodiazepine reasoning from reports on other drugs, and the disease is largely inflammation-driven and resistant to standard antiseizure drugs.

To proceed, the following is needed:

Clobazam-specific case series or registry data in FIRES or related refractory status epilepticus
Detailed mechanism-of-action data and a mechanistic rationale that addresses neuroinflammation
Health Canada package insert warnings and contraindications
A safety plan covering sedation, tolerance, and the drug interactions listed above (particularly with opioids and CYP-metabolised drugs)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.